P14.15: Elevated fetal DNA levels in maternal blood in the 14th week: a case report

2010 ◽  
Vol 36 (S1) ◽  
pp. 221-221
Author(s):  
R. Vlk ◽  
I. Hromadnikova ◽  
M. Simandlova ◽  
M. Hrehorcak ◽  
M. Havlovicova ◽  
...  
Keyword(s):  
Case Report ◽  
Maternal Blood ◽  
Fetal Dna

The cell-free fetal DNA fraction in maternal blood decreases after physical activity

2014 ◽  
Vol 34 (4) ◽  
pp. 341-344 ◽  
Author(s):  
Jacob Mørup Schlütter ◽  
Lotte Hatt ◽  
Cathrine Bach ◽  
Ida Kirkegaard ◽  
Steen Kølvraa ◽  
...  
Keyword(s):  
Physical Activity ◽  
Maternal Blood ◽  
Fetal Dna ◽  
Cell Free Fetal Dna

Successful management of severe hemolytic disease of the fetus due to anti-Jsb using intrauterine transfusions with serial maternal blood donations: a case report and a review of the literature

Transfusion ◽  
2013 ◽  
Vol 54 (1) ◽  
pp. 238-243 ◽  
Author(s):  
Arwa Z. Al Riyami ◽  
Moza Al Salmani ◽  
Sabria Al Hashami ◽  
Sabah Al Mahrooqi ◽  
Sumaiya Al Hinai ◽  
...  
Keyword(s):  
Case Report ◽  
Maternal Blood ◽  
Review Of The Literature ◽  
Hemolytic Disease ◽  
Successful Management ◽  
Blood Donations

scholarly journals Noninvasive Prenatal Detection of Trisomy 21 by an Epigenetic–Genetic Chromosome-Dosage Approach

2010 ◽  
Vol 56 (1) ◽  
pp. 90-98 ◽  
Author(s):  
Yu K Tong ◽  
Shengnan Jin ◽  
Rossa WK Chiu ◽  
Chunming Ding ◽  
KC Allen Chan ◽  
...  
Keyword(s):  
Prenatal Diagnosis ◽  
Genetic Markers ◽  
Blood Cells ◽  
Trisomy 21 ◽  
Maternal Blood ◽  
Maternal Plasma ◽  
Plasma Samples ◽  
Prenatal Detection ◽  
Fetal Dna ◽  
Noninvasive Prenatal Diagnosis

Abstract Background: The use of fetal DNA in maternal plasma for noninvasive prenatal diagnosis of trisomy 21 (T21) is an actively researched area. We propose a novel method of T21 detection that combines fetal-specific epigenetic and genetic markers. Methods: We used combined bisulfite restriction analysis to search for fetal DNA markers on chromosome 21 that were differentially methylated in the placenta and maternal blood cells and confirmed any target locus with bisulfite sequencing. We then used methylation-sensitive restriction endonuclease digestion followed by microfluidics digital PCR analysis to investigate the identified marker. Chromosome-dosage analysis was performed by comparing the dosage of this epigenetic marker with that of the ZFY (zinc finger protein, Y-linked) gene on chromosome Y. Results: The putative promoter of the HLCS (holocarboxylase synthetase) gene was hypermethylated in the placenta and hypomethylated in maternal blood cells. A chromosome-dosage comparison of the hypermethylated HLCS and ZFY loci could distinguish samples of T21 and euploid placental DNA. Twenty-four maternal plasma samples from euploid pregnancies and 5 maternal plasma samples from T21 pregnancies were analyzed. All but 1 of the euploid samples were correctly classified. Conclusions: The epigenetic–genetic chromosome-dosage approach is a new method for noninvasive prenatal detection of T21. The epigenetic part of the analysis can be applied to all pregnancies. Because the genetic part of the analysis uses paternally inherited, fetal-specific genetic markers that are abundant in the genome, broad population coverage should be readily achievable. This approach has the potential to become a generally usable technique for noninvasive prenatal diagnosis.

Examination of Fetal Cells and Cell-Free Fetal DNA in Maternal Blood for Fetal Gender Determination

2004 ◽  
Vol 58 (1) ◽  
pp. 57-60 ◽  
Author(s):  
Xiao Xi Zhao ◽  
Nobuhiro Suzumori ◽  
Yasuhiko Ozaki ◽  
Takeshi Sato ◽  
Kaoru Suzumori
Keyword(s):  
Maternal Blood ◽  
Gender Determination ◽  
Fetal Cells ◽  
Fetal Dna ◽  
Fetal Gender ◽  
Cell Free Fetal Dna

scholarly journals Fetal Sex Determination Using Cell-Free Fetal Dna (cffDNA) in Maternal Blood

2016 ◽  
Vol 5 (2) ◽  
pp. 89 ◽  
Author(s):  
I Nyoman Hariyasa Sanjaya ◽  
Tjok Gde Agung Suwardewa ◽  
I G Kamasan N. Arijana
Keyword(s):  
Sex Determination ◽  
Maternal Blood ◽  
Fetal Sex ◽  
Fetal Dna ◽  
Cell Free Fetal Dna

Zellfreie fetale DNA im mütterlichen Blut: neue Möglichkeiten in der pränatalen Diagnostik/Cell free fetal DNA in maternal blood: new possibilities in prenatal diagnosis

2012 ◽  
Vol 36 (5) ◽  
Author(s):  
Markus Stumm ◽  
Rolf-Dieter Wegner ◽  
Wera Hofmann
Keyword(s):  
Prenatal Diagnosis ◽  
Next Generation Sequencing ◽  
De Novo ◽  
Maternal Blood ◽  
Fetal Dna ◽  
Cell Free Fetal Dna ◽  
Next Generation Sequencing Ngs ◽  
Fetale Dna ◽  
Generation Sequencing ◽  
Zellfreie Fetale Dna

ZusammenfassungDie zellfreie fetale DNA (cff-DNA) im mütterlichen Blut bietet viele neue Möglichkeiten der pränatalen genetischen Diagnostik. Im Gegensatz zu den etablierten invasiven Techniken der Chorionzottenbiopsie (CVS) und der Amniozentese (AC), die beide mit einem spezifischen Risiko (0,5–1%) einer eingriffsbedingten Fehlgeburt einhergehen, ist die Grundlage für die Gewinnung der cff-DNA eine einfache venöse Blutentnahme der Mutter, die keinerlei Risiko für den Embryo oder Feten darstellt. Damit bietet die cff-DNA die Möglichkeit einer risikofreien genetischen Diagnostik von bestehenden Schwangerschaften. Molekulargenetische Techniken werden schon seit längerer Zeit zum qualitativen Nachweis von spezifischen fetalen Sequenzen, wie paternal vererbten oder neu entstandenen (de novo) Mutationen, eingesetzt. Durch den Einsatz digitaler PCR und Next-Generation-Sequencing (NGS) Technologien gelingt mittlerweile aber auch der sichere quantitative Nachweis von mutierten Allelen sowie von klinisch relevanten Aneuploidien (Trisomie 13, 18 und 21) aus fetaler DNA im mütterlichen Blut.

Sign in / Sign up

Export Citation Format

Share Document